Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
Nuo Therapeutics (OTCQB: AURX) has entered a multi-year exclusive agreement with PAM Health to provide its Aurix System as the sole platelet-rich plasma (PRP) wound care therapy across PAM Health's network. The partnership spans all PAM Health's facilities including long-term acute care hospitals, rehabilitation centers, and wound care clinics across 23 states.
The Aurix System, the first FDA-cleared autologous PRP therapy for chronic wounds, utilizes a one-minute spin process to create a biologically active gel from the patient's platelets and plasma. Clinical studies, including collaborations with Medicare & Medicaid Services, have shown superior healing rates compared to other advanced wound modalities.
This partnership addresses a significant healthcare challenge, as chronic wounds affect 2% of the US population and over 8 million Medicare beneficiaries, with annual Medicare spending ranging from $28.1 to $96.8 billion. The condition leads to over 100,000 diabetic amputations annually, with a five-year post-amputation mortality rate of nearly 62%.
Nuo Therapeutics (OTCQB: AURX) ha siglato un accordo esclusivo pluriennale con PAM Health per fornire il suo sistema Aurix come unica terapia a base di plasma ricco di piastrine (PRP) per la cura delle ferite all'interno della rete di PAM Health. La collaborazione coinvolge tutte le strutture di PAM Health, inclusi ospedali per cure acute a lungo termine, centri di riabilitazione e cliniche per la cura delle ferite in 23 stati.
Il sistema Aurix, la prima terapia autologa PRP approvata dalla FDA per ferite croniche, utilizza un processo di centrifugazione di un minuto per creare un gel biologicamente attivo dalle piastrine e dal plasma del paziente. Studi clinici, comprese collaborazioni con Medicare & Medicaid Services, hanno dimostrato tassi di guarigione superiori rispetto ad altre modalità avanzate di trattamento delle ferite.
Questa partnership affronta una sfida significativa nel settore sanitario, poiché le ferite croniche colpiscono il 2% della popolazione statunitense e oltre 8 milioni di beneficiari Medicare, con una spesa annua di Medicare che varia da 28,1 a 96,8 miliardi di dollari. La condizione provoca oltre 100.000 amputazioni diabetiche ogni anno, con un tasso di mortalità a cinque anni post-amputazione di quasi il 62%.
Nuo Therapeutics (OTCQB: AURX) ha firmado un acuerdo exclusivo plurianual con PAM Health para proveer su sistema Aurix como la única terapia de plasma rico en plaquetas (PRP) para el cuidado de heridas en toda la red de PAM Health. La colaboración abarca todas las instalaciones de PAM Health, incluyendo hospitales de cuidados agudos a largo plazo, centros de rehabilitación y clínicas de cuidado de heridas en 23 estados.
El sistema Aurix, la primera terapia autóloga de PRP aprobada por la FDA para heridas crónicas, utiliza un proceso de centrifugación de un minuto para crear un gel biológicamente activo a partir de las plaquetas y el plasma del paciente. Estudios clínicos, incluyendo colaboraciones con Medicare & Medicaid Services, han demostrado tasas de curación superiores en comparación con otras modalidades avanzadas para el tratamiento de heridas.
Esta asociación aborda un desafío importante en el sector salud, ya que las heridas crónicas afectan al 2% de la población de EE.UU. y a más de 8 millones de beneficiarios de Medicare, con un gasto anual de Medicare que oscila entre 28,1 y 96,8 mil millones de dólares. La condición provoca más de 100,000 amputaciones diabéticas anuales, con una tasa de mortalidad a cinco años después de la amputación de casi el 62%.
Nuo Therapeutics (OTCQB: AURX)는 PAM Health와 다년간의 독점 계약을 체결하여 PAM Health 네트워크 전반에 걸쳐 혈소판 풍부 혈장(PRP) 상처 치료제로서 Aurix 시스템을 단독으로 제공하게 되었습니다. 이 파트너십은 23개 주에 걸친 PAM Health의 장기 급성 치료 병원, 재활 센터, 상처 치료 클리닉 등 모든 시설을 포함합니다.
Aurix 시스템은 만성 상처 치료를 위한 최초의 FDA 승인 자가 PRP 치료제로, 환자의 혈소판과 혈장에서 생물학적으로 활성화된 젤을 1분간 원심분리하는 과정을 통해 만듭니다. Medicare & Medicaid Services와의 협력을 포함한 임상 연구에서 다른 첨단 상처 치료법에 비해 우수한 치유율을 입증했습니다.
이 파트너십은 만성 상처가 미국 인구의 2%와 800만 명 이상의 Medicare 수혜자에게 영향을 미치며, Medicare 연간 지출이 281억에서 968억 달러에 이르는 심각한 의료 문제를 해결합니다. 이 상태는 매년 10만 건 이상의 당뇨병 절단을 초래하며, 절단 후 5년 내 사망률은 거의 62%에 달합니다.
Nuo Therapeutics (OTCQB : AURX) a conclu un accord exclusif pluriannuel avec PAM Health pour fournir son système Aurix comme unique thérapie de soins des plaies par plasma riche en plaquettes (PRP) dans le réseau PAM Health. Ce partenariat couvre toutes les installations de PAM Health, y compris les hôpitaux de soins aigus de longue durée, les centres de rééducation et les cliniques de soins des plaies dans 23 États.
Le système Aurix, première thérapie autologue PRP approuvée par la FDA pour les plaies chroniques, utilise un processus de centrifugation d'une minute pour créer un gel biologiquement actif à partir des plaquettes et du plasma du patient. Des études cliniques, incluant des collaborations avec Medicare & Medicaid Services, ont démontré des taux de guérison supérieurs comparés à d'autres modalités avancées de traitement des plaies.
Ce partenariat répond à un défi majeur de santé publique, car les plaies chroniques affectent 2 % de la population américaine et plus de 8 millions de bénéficiaires de Medicare, avec des dépenses annuelles de Medicare allant de 28,1 à 96,8 milliards de dollars. Cette condition entraîne plus de 100 000 amputations diabétiques chaque année, avec un taux de mortalité à cinq ans post-amputation de près de 62 %.
Nuo Therapeutics (OTCQB: AURX) hat eine mehrjährige Exklusivvereinbarung mit PAM Health abgeschlossen, um sein Aurix-System als einzige plättchenreiche Plasma(PRP)-Wundtherapie im gesamten Netzwerk von PAM Health bereitzustellen. Die Partnerschaft umfasst alle Einrichtungen von PAM Health, darunter Langzeit-Akutkrankenhäuser, Rehabilitationszentren und Wundkliniken in 23 Bundesstaaten.
Das Aurix-System, die erste von der FDA zugelassene autologe PRP-Therapie für chronische Wunden, verwendet einen einminütigen Zentrifugationsprozess, um ein biologisch aktives Gel aus den Blutplättchen und dem Plasma des Patienten herzustellen. Klinische Studien, einschließlich Kooperationen mit Medicare & Medicaid Services, haben überlegene Heilungsraten im Vergleich zu anderen fortschrittlichen Wundbehandlungsverfahren gezeigt.
Diese Partnerschaft adressiert eine bedeutende gesundheitliche Herausforderung, da chronische Wunden 2 % der US-Bevölkerung und über 8 Millionen Medicare-Empfänger betreffen, mit jährlichen Medicare-Ausgaben zwischen 28,1 und 96,8 Milliarden US-Dollar. Die Erkrankung führt jährlich zu über 100.000 diabetischen Amputationen, mit einer Fünf-Jahres-Mortalitätsrate nach Amputation von fast 62 %.
- Secured exclusive multi-year agreement with PAM Health network of over 100 hospitals and clinics
- Expanding market reach across 23 states through PAM Health's network
- Clinical studies demonstrate superior healing rates compared to other advanced wound modalities
- Targeting large market opportunity with 8 million+ Medicare beneficiaries affected by chronic wounds
- Operating in highly competitive wound care market with $28.1-96.8B Medicare spending
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chronic wound healing. A multi-year exclusive agreement between PAM Health and Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company at the forefront of biodynamic therapies, means Nuo’s Aurix System will serve as the sole platelet-rich plasma (PRP) wound care therapy across all of PAM Health’s long-term acute care hospitals, inpatient rehabilitation hospitals, and outpatient and wound care clinics. This collaboration will make advanced regenerative treatment more widely available for patients suffering from chronic non-healing wounds.
Representing a silent epidemic in the United States, chronic wounds annually affect an estimated
“The collaboration with PAM Health is about more than product distribution, it’s about aligning missions,” said Dave Hazard, Nuo’s Vice President, Sales. “PAM Health is a trusted leader in patient care. Their clinical reach across 23 states positions them to significantly expand access to the Aurix System. Together, we aim to reduce complications, improve healing times, and most importantly, elevate patient outcomes.”
The Aurix System is the first FDA-cleared autologous PRP therapy specifically indicated for the management of chronic wounds. With a streamlined, one-minute spin process, Aurix produces a biologically active gel using a patient's own platelets and plasma, supporting healing through the natural regenerative cycle. Clinical studies, including those in collaboration with the Centers for Medicare & Medicaid Services, have demonstrated Aurix’s success in accelerating healing compared to other advanced wound modalities.
“At PAM Health, we are committed to delivering clinical excellence to our patients through evidence-based, outcome-driven therapies,” said Nick Fazzolari, SVP, Chief Business Officer, PAM Health. “Adding the Aurix System to our advanced wound care services reflects our unwavering dedication to innovative, patient-centered solutions that optimize healing, reduce complications, and support long-term well-being. This collaboration is a natural extension of our mission to deliver transformative care solutions and reflects the values guiding our pursuit of excellence across the post-acute continuum.”
With over 100 hospitals and specialty clinics, PAM Health continues to lead by example, integrating data-driven innovation and compassionate care. The integration of Aurix PRP into its wound care services reflects PAM Health’s broader strategic vision to provide comprehensive, cost-effective care solutions for patients with complex, chronic conditions, particularly those at risk of limb loss and hospital readmission.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company pioneering biodynamic therapies that harness the body’s innate healing abilities. The company’s flagship product, the Aurix System, is an FDA-cleared autologous PRP therapy indicated for the management of chronic wounds. Learn more at www.nuot.com.
About PAM Health
PAM Health, based in Enola, Pennsylvania, provides post-acute healthcare services through more than 100 long-term acute care hospitals, medical rehabilitation hospitals, behavioral health hospitals, as well as wound care clinics and outpatient physical therapy locations, in 23 states. PAM Health is committed to providing high-quality patient care and outstanding customer service, coupled with loyal, dedicated, and highly trained staff, to be the most trusted and impactful source for healthcare services in every community it serves. Learn more at PAMHealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo's management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in the Nuo's public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo's annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
References
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017). Diabetic foot ulcers and their recurrence. The New England Journal of Medicine, 376(24), 2367-2375.
https://doi.org/10.1056/NEJMra1615439
Nussbaum, S. R., Carter, M. J., Fife, C. E., DaVanzo, J. E., Haught, R., Nusgart, M., & Cartwright, D. (2018). An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. Value in Health, 21(1), 27–32.
https://doi.org/10.1016/j.jval.2017.07.007
Rice, J. B., Desai, U., Cummings, A. K. G., Birnbaum, H. G., Skornicki, M., & Parsons, N. (2014). Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care, 37(3), 651–658.
https://doi.org/10.2337/dc13-2176
David Jorden
djorden@nuot.com
FAQ
What is the financial impact of chronic wounds on Medicare spending according to the AURX press release?
How many states will the AURX Aurix System be available through the PAM Health partnership?
What makes the AURX Aurix System unique in wound care treatment?
What is the scope of the chronic wound problem that AURX's Aurix System addresses?
